


## Levobunolol hydrochloride

## Chemical Properties

CAS No. :	27912-14-7
Formula:	C <sub>17</sub> H <sub>26</sub> ClNO <sub>3</sub>
Molecular Weight:	327.85
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Levobunolol hydrochloride is a non-selective blocker of $\beta$ -adrenergic receptor and can be used in studies about managing glaucoma and superior oblique myokymia.
Targets(IC50)	Adrenergic Receptor

## Solubility Information

Solubility	H <sub>2</sub> O: 50 mg/mL (152.51 mM), Sonication is recommended. DMSO: 56.3 mg/mL (171.72 mM), Sonication is recommended. ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.5 mg/mL (7.63 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.0502 mL	15.2509 mL	30.5018 mL
5 mM	0.610 mL	3.0502 mL	6.1004 mL
10 mM	0.305 mL	1.5251 mL	3.0502 mL
50 mM	0.061 mL	0.305 mL	0.610 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Kumar, N, et al. Extended levobunolol release from Eudragit nanoparticle-laden contact lenses for glaucoma therapy. *Futur J Pharm Sci* 6, 109 (2020).

Zhang M, et al. Superior oblique myokymia treated with levobunolol. *J AAPOS*. 2018 Feb;22(1):67-69.e2.

Mohammadi M, et al. Injectable drug depot engineered to release multiple ophthalmic therapeutic agents with precise time profiles for postoperative treatment following ocular surgery. *Acta Biomater*. 2018 Jun;73:90-102.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481